Results 11 to 20 of about 3,780 (183)

Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry. [PDF]

open access: yesBr J Haematol, 2021
Summary Autoimmune disease is a risk factor for first incident venous thromboembolism (VTE). However, data on the risk of recurrent VTE in people with autoimmune disease is sparse. We explored the risk of recurrent VTE using the RIETE registry, comparing people with autoimmune disease (n = 1305) to those without (n = 50608).
Borjas Howard J   +10 more
europepmc   +2 more sources

Safety of the pulmonary embolism rule‐out criteria rule: Findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) registry

open access: yesAcademic Emergency Medicine, Volume 30, Issue 9, Page 935-945, September 2023., 2023
Abstract Background The diagnostic strategy for pulmonary embolism (PE) includes a D‐dimer test when PE probability is low or intermediate, but false‐positive D‐dimer results are frequent and can result in an unnecessary computed tomography pulmonary angiogram.
Perrine Truong   +204 more
wiley   +1 more source

Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

open access: yesBritish Journal of Haematology, Volume 201, Issue 5, Page 971-981, June 2023., 2023
Summary Predictive tools for major bleeding (MB) using machine learning (ML) might be advantageous over traditional methods. We used data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) to develop ML algorithms to identify patients with venous thromboembolism (VTE) at increased risk of MB during the first 3 months of ...
Damián Mora   +207 more
wiley   +1 more source

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

open access: yesResearch and Practice in Thrombosis and Haemostasis, Volume 6, Issue 4, May 2022., 2022
Abstract Background Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death. Objectives The objective of the RIETECAT study was to compare the long‐term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondary prevention of VTE in adults with active ...
Javier Trujillo‐Santos   +182 more
wiley   +1 more source

Right heart thrombi (RHT) and clot in transit with concomitant PE management: Approach and considerations

open access: yesPulmonary Circulation, Volume 12, Issue 2, April 2022., 2022
Abstract Right heart thrombi (RHT) continues to pose a clinical dilemma for multiple specialties and is especially concerning when present with concomitant pulmonary embolism (PE). Patients with PE and RHT are at an increased risk of poor outcomes compared to PE without RHT. Although the exact incidence of RHT is unknown, the increasing use of point‐of‐
Akhil Khosla   +5 more
wiley   +1 more source

Failure rate of the pulmonary embolism rule-out criteria rule for adults 35 years or younger: Findings from the RIETE Registry. [PDF]

open access: yesAcad Emerg Med
Abstract Background The use of a computed tomography pulmonary angiogram to diagnose pulmonary embolism (PE) has increased, leading not only to higher PE diagnoses but also to overdiagnosis and unnecessary radiation exposure, even in young patients despite a lower PE incidence.
Jossein T   +10 more
europepmc   +2 more sources

International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis

open access: yesJournal of Thrombosis and Haemostasis, Volume 19, Issue 4, Page 1123-1129, April 2021., 2021
Abstract Pediatric thromboembolism is a rare and heterogenous disease. As a result, there is a paucity of knowledge with regard to natural history, management, and outcomes of most types of pediatric venous and arterial thromboembolism. International research collaboration is needed to fill these knowledge gaps.
C. Heleen van Ommen   +17 more
wiley   +1 more source

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies

open access: yesResearch and Practice in Thrombosis and Haemostasis, Volume 5, Issue 3, Page 426-438, March 2021., 2021
Abstract Background The XALIA and XALIA‐LEA prospective, noninterventional studies investigated the safety and effectiveness of rivaroxaban versus standard anticoagulation for venous thromboembolism (VTE) treatment in routine clinical practice across global regions.
Sylvia Haas   +10 more
wiley   +1 more source

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE

open access: yesResearch and Practice in Thrombosis and Haemostasis, Volume 5, Issue 2, Page 326-341, February 2021., 2021
Abstract Introduction Venous thromboembolism (VTE) has a long‐term risk of recurrence, dependent on the presence or absence of provoking risk factors at the time of the event. Objective To compare clinical characteristics, anticoagulant patterns, and 12‐month outcomes in patients with transient provoking factors, active cancer, and unprovoked VTE ...
Walter Ageno   +14 more
wiley   +1 more source

Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

open access: yesResearch and Practice in Thrombosis and Haemostasis, Volume 5, Issue 1, Page 168-178, January 2021., 2021
Abstract Background The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. Methods We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental, segmental, or more central PEs.
Carmen Fernández‐Capitán   +161 more
wiley   +1 more source

Home - About - Disclaimer - Privacy